invivodata Co-Founder Dr. Saul Shiffman Recognized by Carnegie Science Awards

Share Article

Shiffman Recognized for Groundbreaking Research in Patient Data Collection

News Image
Helping develop PRO science in clinical trials has been a rewarding endeavor, and having the work recognized in this manner is both gratifying and humbling," said Dr. Shiffman

invivodata inc. ®, the industry leader in reliable electronic solutions and strategic consulting services for successful Clinical Outcome Assessment (COA) data collection in global clinical research, today announced that its co-founder and chief science officer, Dr. Saul Shiffman, has been recognized by the Carnegie Science Center as an honorable mention in the Entrepreneur Category of its 2012 Carnegie Science Awards.

“Carnegie Science Awards recognize and promote outstanding science and technology achievements in western Pennsylvania,” said Ann Metzger, Co-Director of Carnegie Science Center. “We are pleased to add Dr. Shiffman to a distinguished list of 300 individuals and organizations that have been honored since 1997 for improving lives through their commitment and contributions in science and technology.”

Dr. Shiffman is being recognized for his ground-breaking research in the scientific methods and processes that drive patient behavior to produce valid and reliable data and for his development of the first handheld computer solution for collecting patient data during clinical research, which are the foundation of today’s electronic Patient Reported Outcomes (ePRO) industry.

”Working with Saul and watching his concepts for real-time, real-world data collection through ePRO become so widely adopted has been exhilarating,” said Doug Engfer, invivodata President and CEO. “We founded invivodata to further develop the commercial applications of this technology and are extremely gratified by the positive effect it continues to have on the clinical research industry.”

“I am proud to have been recognized by this award. Helping develop PRO science in clinical trials has been a rewarding endeavor, and having the work recognized in this manner is both gratifying and humbling. This honor also reinforces our belief in the importance of keeping clinical research focused on the patient, which is our top priority,” said Dr. Shiffman.

About invivodata
invivodata is the only fully-integrated Clinical Outcomes Assessments (COA) company delivering regulatory-proven strategic consulting and practical electronic solutions to biopharmaceutical companies who depend upon patient-centered research. From reliable and scientifically sound consulting that helps research teams effectively develop, execute, and document COA strategies to electronically collecting COA data in global clinical development programs, invivodata helps its customers strategically use patient-, clinician-, and observer-reported outcomes data (PROs, ClinROs & ObsROs) to support labeling claims, enhance reimbursement strategies, and meet other clinical program objectives. Through partnerships with leading CROs and eClinical technology providers, invivodata seamlessly integrates into the clinical trial ecosystem, helping to minimize operational risk and maximize efficiencies. invivodata’s electronic solutions and strategic consulting services have been used in over 600 clinical programs and are built upon the industry-leading ePRO system in delivering primary efficacy data for global drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, PA., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, CA., USA. For more information, visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Christine Tobin
invivodata (SBE)
412-390-3000 3502
Email >
Visit website